Global Circulating Tumor Cells (CTC)

Circulating Tumor Cells (CTC) Comprehensive Study by Type (Ex-Vivo Positive Selection, In-Vivo Positive Selection, Negative Selection, Microchips & Single Spiral Micro Channel), Application (Tumorigenesis Research, Emt Biomarkers Development, Cancer Stem Cell Research, Others) Players and Region - Global Market Outlook to 2028

Circulating Tumor Cells (CTC) Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The Circulating Tumor Cells refers to the tumor cells, which are circulating inside the body through the blood circulation system and lymphatic system. These are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Moreover, the growth in the developments of numerous tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer is boosting the growth of the very market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledTATAA Biocenter (AdnaGen) (Sweden), Precision for Medicine, Inc. (Apocell Inc.) (United States), Biocep Ltd. (Israel), Canopus Bioscience Ltd. (Canada), Creatv Microtech (United States), Ikonisys Inc. (United States), Miltenyi Biotech (Germany), Nanostring Technologies (United States), Rarecells Diagnostics (France) and Vitatex (United States)


This growth is primarily driven by Technological Advancements in Biomedical Imaging and Bioengineering Technology, Rising Demand for Preventive Medicine and Companion Diagnostics Worldwide and Increasing Prevalence of Cancer Across the Globe.

Globally, a noticeable market trend is evident Presence of Target Population and Surging Investments in R&D by Key Market Players Major Players, such as TATAA Biocenter (AdnaGen) (Sweden), Precision for Medicine, Inc. (Apocell Inc.) (United States), Biocep Ltd. (Israel), Canopus Bioscience Ltd. (Canada), Creatv Microtech (United States), Ikonisys Inc. (United States), Miltenyi Biotech (Germany), Nanostring Technologies (United States), Rarecells Diagnostics (France) and Vitatex (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The competitive landscape of the circulating tumor cells (CTC) liquid biopsy market gives information by competitor. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The data points mentioned above only pertain to the companies' focus on the liquid biopsy market for circulating tumor cells (CTC).

In 2021, Ikonisys launched Next Generation of CTC Detection, Analysis Platform; Expands US Presence

Influencing Trend:
Presence of Target Population and Surging Investments in R&D by Key Market Players

Market Growth Drivers:
Technological Advancements in Biomedical Imaging and Bioengineering Technology, Rising Demand for Preventive Medicine and Companion Diagnostics Worldwide and Increasing Prevalence of Cancer Across the Globe

Challenges:
Lack of Awareness and Unwillingness for the Adoption of Advanced CTC Technologies

Restraints:
Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis

Opportunities:
Increasing Government Funding to Various Institutes for Research in both Developing and Developed Economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Circulating Tumor Cells (CTC) Market
- Analysis about New Entrants in Circulating Tumor Cells (CTC) Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Circulating Tumor Cells (CTC) Study Sheds Light on
— The Circulating Tumor Cells (CTC) Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Circulating Tumor Cells (CTC) industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Circulating Tumor Cells (CTC) industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Ex-Vivo Positive Selection
  • In-Vivo Positive Selection
  • Negative Selection
  • Microchips & Single Spiral Micro Channel
By Application
  • Tumorigenesis Research
  • Emt Biomarkers Development
  • Cancer Stem Cell Research
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technological Advancements in Biomedical Imaging and Bioengineering Technology
      • 3.2.2. Rising Demand for Preventive Medicine and Companion Diagnostics Worldwide
      • 3.2.3. Increasing Prevalence of Cancer Across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness and Unwillingness for the Adoption of Advanced CTC Technologies
    • 3.4. Market Trends
      • 3.4.1. Presence of Target Population and Surging Investments in R&D by Key Market Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Circulating Tumor Cells (CTC), by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Circulating Tumor Cells (CTC) (Value)
      • 5.2.1. Global Circulating Tumor Cells (CTC) by: Type (Value)
        • 5.2.1.1. Ex-Vivo Positive Selection
        • 5.2.1.2. In-Vivo Positive Selection
        • 5.2.1.3. Negative Selection
        • 5.2.1.4. Microchips & Single Spiral Micro Channel
      • 5.2.2. Global Circulating Tumor Cells (CTC) by: Application (Value)
        • 5.2.2.1. Tumorigenesis Research
        • 5.2.2.2. Emt Biomarkers Development
        • 5.2.2.3. Cancer Stem Cell Research
        • 5.2.2.4. Others
      • 5.2.3. Global Circulating Tumor Cells (CTC) Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Circulating Tumor Cells (CTC): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. TATAA Biocenter (AdnaGen) (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Precision for Medicine, Inc. (Apocell Inc.) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocep Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Canopus Bioscience Ltd. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Creatv Microtech (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ikonisys Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Miltenyi Biotech (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nanostring Technologies (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rarecells Diagnostics (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Vitatex (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Circulating Tumor Cells (CTC) Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Circulating Tumor Cells (CTC) (Value)
      • 7.2.1. Global Circulating Tumor Cells (CTC) by: Type (Value)
        • 7.2.1.1. Ex-Vivo Positive Selection
        • 7.2.1.2. In-Vivo Positive Selection
        • 7.2.1.3. Negative Selection
        • 7.2.1.4. Microchips & Single Spiral Micro Channel
      • 7.2.2. Global Circulating Tumor Cells (CTC) by: Application (Value)
        • 7.2.2.1. Tumorigenesis Research
        • 7.2.2.2. Emt Biomarkers Development
        • 7.2.2.3. Cancer Stem Cell Research
        • 7.2.2.4. Others
      • 7.2.3. Global Circulating Tumor Cells (CTC) Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Circulating Tumor Cells (CTC): by Type(USD Million)
  • Table 2. Circulating Tumor Cells (CTC) Ex-Vivo Positive Selection , by Region USD Million (2017-2022)
  • Table 3. Circulating Tumor Cells (CTC) In-Vivo Positive Selection , by Region USD Million (2017-2022)
  • Table 4. Circulating Tumor Cells (CTC) Negative Selection , by Region USD Million (2017-2022)
  • Table 5. Circulating Tumor Cells (CTC) Microchips & Single Spiral Micro Channel , by Region USD Million (2017-2022)
  • Table 6. Circulating Tumor Cells (CTC): by Application(USD Million)
  • Table 7. Circulating Tumor Cells (CTC) Tumorigenesis Research , by Region USD Million (2017-2022)
  • Table 8. Circulating Tumor Cells (CTC) Emt Biomarkers Development , by Region USD Million (2017-2022)
  • Table 9. Circulating Tumor Cells (CTC) Cancer Stem Cell Research , by Region USD Million (2017-2022)
  • Table 10. Circulating Tumor Cells (CTC) Others , by Region USD Million (2017-2022)
  • Table 11. South America Circulating Tumor Cells (CTC), by Country USD Million (2017-2022)
  • Table 12. South America Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 13. South America Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 14. Brazil Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 15. Brazil Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 16. Argentina Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 17. Argentina Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 18. Rest of South America Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 19. Rest of South America Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 20. Asia Pacific Circulating Tumor Cells (CTC), by Country USD Million (2017-2022)
  • Table 21. Asia Pacific Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 22. Asia Pacific Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 23. China Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 24. China Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 25. Japan Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 26. Japan Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 27. India Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 28. India Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 29. South Korea Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 30. South Korea Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 31. Taiwan Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 32. Taiwan Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 33. Australia Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 34. Australia Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 36. Rest of Asia-Pacific Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 37. Europe Circulating Tumor Cells (CTC), by Country USD Million (2017-2022)
  • Table 38. Europe Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 39. Europe Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 40. Germany Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 41. Germany Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 42. France Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 43. France Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 44. Italy Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 45. Italy Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 46. United Kingdom Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 47. United Kingdom Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 48. Netherlands Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 49. Netherlands Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 50. Rest of Europe Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 51. Rest of Europe Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 52. MEA Circulating Tumor Cells (CTC), by Country USD Million (2017-2022)
  • Table 53. MEA Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 54. MEA Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 55. Middle East Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 56. Middle East Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 57. Africa Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 58. Africa Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 59. North America Circulating Tumor Cells (CTC), by Country USD Million (2017-2022)
  • Table 60. North America Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 61. North America Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 62. United States Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 63. United States Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 64. Canada Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 65. Canada Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 66. Mexico Circulating Tumor Cells (CTC), by Type USD Million (2017-2022)
  • Table 67. Mexico Circulating Tumor Cells (CTC), by Application USD Million (2017-2022)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Circulating Tumor Cells (CTC): by Type(USD Million)
  • Table 79. Circulating Tumor Cells (CTC) Ex-Vivo Positive Selection , by Region USD Million (2023-2028)
  • Table 80. Circulating Tumor Cells (CTC) In-Vivo Positive Selection , by Region USD Million (2023-2028)
  • Table 81. Circulating Tumor Cells (CTC) Negative Selection , by Region USD Million (2023-2028)
  • Table 82. Circulating Tumor Cells (CTC) Microchips & Single Spiral Micro Channel , by Region USD Million (2023-2028)
  • Table 83. Circulating Tumor Cells (CTC): by Application(USD Million)
  • Table 84. Circulating Tumor Cells (CTC) Tumorigenesis Research , by Region USD Million (2023-2028)
  • Table 85. Circulating Tumor Cells (CTC) Emt Biomarkers Development , by Region USD Million (2023-2028)
  • Table 86. Circulating Tumor Cells (CTC) Cancer Stem Cell Research , by Region USD Million (2023-2028)
  • Table 87. Circulating Tumor Cells (CTC) Others , by Region USD Million (2023-2028)
  • Table 88. South America Circulating Tumor Cells (CTC), by Country USD Million (2023-2028)
  • Table 89. South America Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 90. South America Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 91. Brazil Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 92. Brazil Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 93. Argentina Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 94. Argentina Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 95. Rest of South America Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 96. Rest of South America Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 97. Asia Pacific Circulating Tumor Cells (CTC), by Country USD Million (2023-2028)
  • Table 98. Asia Pacific Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 99. Asia Pacific Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 100. China Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 101. China Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 102. Japan Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 103. Japan Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 104. India Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 105. India Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 106. South Korea Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 107. South Korea Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 108. Taiwan Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 109. Taiwan Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 110. Australia Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 111. Australia Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 112. Rest of Asia-Pacific Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 113. Rest of Asia-Pacific Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 114. Europe Circulating Tumor Cells (CTC), by Country USD Million (2023-2028)
  • Table 115. Europe Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 116. Europe Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 117. Germany Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 118. Germany Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 119. France Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 120. France Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 121. Italy Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 122. Italy Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 123. United Kingdom Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 124. United Kingdom Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 125. Netherlands Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 126. Netherlands Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 127. Rest of Europe Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 128. Rest of Europe Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 129. MEA Circulating Tumor Cells (CTC), by Country USD Million (2023-2028)
  • Table 130. MEA Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 131. MEA Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 132. Middle East Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 133. Middle East Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 134. Africa Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 135. Africa Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 136. North America Circulating Tumor Cells (CTC), by Country USD Million (2023-2028)
  • Table 137. North America Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 138. North America Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 139. United States Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 140. United States Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 141. Canada Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 142. Canada Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 143. Mexico Circulating Tumor Cells (CTC), by Type USD Million (2023-2028)
  • Table 144. Mexico Circulating Tumor Cells (CTC), by Application USD Million (2023-2028)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Circulating Tumor Cells (CTC): by Type USD Million (2017-2022)
  • Figure 5. Global Circulating Tumor Cells (CTC): by Application USD Million (2017-2022)
  • Figure 6. South America Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 7. Asia Pacific Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 8. Europe Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 9. MEA Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 10. North America Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 11. Global Circulating Tumor Cells (CTC) share by Players 2022 (%)
  • Figure 12. Global Circulating Tumor Cells (CTC) share by Players (Top 3) 2022(%)
  • Figure 13. Global Circulating Tumor Cells (CTC) share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. TATAA Biocenter (AdnaGen) (Sweden) Revenue, Net Income and Gross profit
  • Figure 16. TATAA Biocenter (AdnaGen) (Sweden) Revenue: by Geography 2022
  • Figure 17. Precision for Medicine, Inc. (Apocell Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 18. Precision for Medicine, Inc. (Apocell Inc.) (United States) Revenue: by Geography 2022
  • Figure 19. Biocep Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Biocep Ltd. (Israel) Revenue: by Geography 2022
  • Figure 21. Canopus Bioscience Ltd. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Canopus Bioscience Ltd. (Canada) Revenue: by Geography 2022
  • Figure 23. Creatv Microtech (United States) Revenue, Net Income and Gross profit
  • Figure 24. Creatv Microtech (United States) Revenue: by Geography 2022
  • Figure 25. Ikonisys Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Ikonisys Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Miltenyi Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Miltenyi Biotech (Germany) Revenue: by Geography 2022
  • Figure 29. Nanostring Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 30. Nanostring Technologies (United States) Revenue: by Geography 2022
  • Figure 31. Rarecells Diagnostics (France) Revenue, Net Income and Gross profit
  • Figure 32. Rarecells Diagnostics (France) Revenue: by Geography 2022
  • Figure 33. Vitatex (United States) Revenue, Net Income and Gross profit
  • Figure 34. Vitatex (United States) Revenue: by Geography 2022
  • Figure 35. Global Circulating Tumor Cells (CTC): by Type USD Million (2023-2028)
  • Figure 36. Global Circulating Tumor Cells (CTC): by Application USD Million (2023-2028)
  • Figure 37. South America Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 38. Asia Pacific Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 39. Europe Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 40. MEA Circulating Tumor Cells (CTC) Share (%), by Country
  • Figure 41. North America Circulating Tumor Cells (CTC) Share (%), by Country
List of companies from research coverage that are profiled in the study
  • TATAA Biocenter (AdnaGen) (Sweden)
  • Precision for Medicine, Inc. (Apocell Inc.) (United States)
  • Biocep Ltd. (Israel)
  • Canopus Bioscience Ltd. (Canada)
  • Creatv Microtech (United States)
  • Ikonisys Inc. (United States)
  • Miltenyi Biotech (Germany)
  • Nanostring Technologies (United States)
  • Rarecells Diagnostics (France)
  • Vitatex (United States)
Select User Access Type

Key Highlights of Report


May 2023 246 Pages 92 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Circulating Tumor Cells (CTC) Quantitative research analysis
Global Circulating Tumor Cells (CTC) Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Circulating Tumor Cells (CTC) market are TATAA Biocenter (AdnaGen) (Sweden), Precision for Medicine, Inc. (Apocell Inc.) (United States), Biocep Ltd. (Israel), Canopus Bioscience Ltd. (Canada), Creatv Microtech (United States), Ikonisys Inc. (United States), Miltenyi Biotech (Germany), Nanostring Technologies (United States), Rarecells Diagnostics (France) and Vitatex (United States), to name a few.
is dominating the Circulating Tumor Cells (CTC) Market.
"Lack of Awareness and Unwillingness for the Adoption of Advanced CTC Technologies" is seen as one of the major challenges by many Industry Players of Circulating Tumor Cells (CTC) Market
The Circulating Tumor Cells (CTC) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Circulating Tumor Cells (CTC) market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Circulating Tumor Cells (CTC) Report?

Have a Query? Click Here

Other Related Reports

Sleep Disorder Therapeutics Comprehensive Study by Type (Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others), Medical Devices) Players and ...
$ 3500
Shingles Treatments Comprehensive Study by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams, Others), Route of Administration ...
$ 3450
Schizophrenia Treatments Comprehensive Study by Type (Medications, Conventional or Typical Antipsychotic Drugs, Atypical Antipsychotic Drugs, Therapies), End Users (Hospital Pharmacies, Drug Stores, ...
$ 3650
Sarcopenia Treatment Comprehensive Study by Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Ho...
$ 3350
Critical Limb Ischemia Treatment Comprehensive Study by Type (Medications (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Others), Endovascular Treatments, Surgery), Application ...
$ 3450
Prostatic Artery Embolization Comprehensive Study by Type (Guidewires, Micro catheters, Microspheres), Application (Hospitals, Ambulatory Surgical centers, Specialty clinics) Players and Region - Glo...
$ 3500